AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35572740
Drug: PVP-I nasal
RxNorm normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVP-I nasal spray (NS) at diluted concentrations of 0.6%
Trial: 35573002
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for chronic-active antibody-mediated rejection (caABMR)
Trial: 35574368
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy (NACT)
Trial: 35574426
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily (b.d.)
Trial: 35574426
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg twice daily (b.d.)
Trial: 35574956
Drug: Kidney injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney injury molecule-1 and interleukin-18
Trial: 35575974
Drug: DTaP-IPV vaccine
RxNorm normalized name: DTaP-IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV vaccine (TETRAXIM™)
Trial: 35576349
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal Acetate with adjunct Misoprostol
Trial: 35576508
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus nivolumab (paclitaxel 200 mg/m2)
Trial: 35576508
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus nivolumab
Trial: 35576529
Drug: Mitapivat (AG-348)
RxNorm normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitapivat (AG-348) 50 mg BID
Trial: 35576960
Drug: Navitoclax plus
RxNorm normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navitoclax plus ruxolitinib (navitoclax orally administered at 50 mg per day, escalated weekly to a maximum of 300 mg per day)
Trial: 35577503
Drug: Emactuzumab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emactuzumab (1000 mg) + Atezolizumab (1200 mg)
Trial: 35577814
Drug: Flexible insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible insulin therapy (FIT) with heart rate sensors and automated closed insulin loop
Trial: 35578270
Drug: Aggressive interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aggressive interventions (hospital death, anti-cancer treatment, more than 14 days in hospital, more than one hospital admission, more than one emergency room visit, at least one ICU admission)
Trial: 35578615
Drug: Granola with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granola with low beta-glucan (0.8 g)
Trial: 35578615
Drug: Granola with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granola with medium beta-glucan (3.2 g)
Trial: 35578615
Drug: Granola with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granola with high beta-glucan (6.6 g)
Trial: 35578615
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 ml low-fat milk)
Trial: 35578807
Drug: Chronic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic metformin treatment with aerobic training (EXER+MET)
Trial: 35578807
Drug: Aerobic training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic training without metformin (EXER)
Trial: 35578807
Drug: Chronic metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic metformin treatment
Trial: 35579486
Drug: Medication iatrogenic
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication iatrogenic assessment using Trivalle score
Trial: 35579486
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of potentially inappropriate medications
Trial: 35579486
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of benzodiazepine prescriptions
Trial: 35579486
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of anticholinergic prescriptions
Trial: 35579731
Drug: KX2-391 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KX2-391 120 mg
Trial: 35579731
Drug: KX2-391 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KX2-391 160 mg
Trial: 35579731
Drug: KX2-391 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KX2-391 140 mg
Trial: 35579840
Drug: Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Dose (MD) of MVC-COV1901
Trial: 35579840
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) of MVC-COV1901
Trial: 35579840
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) of MVC-COV1901
Trial: 35579840
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of MVC-COV1901
Trial: 35579840
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of MVC-COV1901
Trial: 35579862
Drug: Naxitamab in
RxNorm normalized name: naxitamab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naxitamab in combination with granulocyte-macrophage colony-stimulating factor
Trial: 35580913
Drug: Prereferral rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prereferral rectal artesunate (RAS)
Trial: 35581627
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg t-PA with 5 mg DNase administered over 24 h
Trial: 35585554
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein intake (0.8-1.2 g/kg)
Trial: 35585554
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (< 0.8 g/kg)
Trial: 35585554
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein intake (> 1.2 g/kg)
Trial: 35585867
Drug: Transcranial Electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial Electromagnetic Treatment (TEMT)
Trial: 35587408
Drug: Adolescent Identity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent Identity Treatment (AIT)
Trial: 35587487
Drug: Everolimus (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (4.5 mg/m2 daily for 7 days)
Trial: 35587536
Drug: Prophylactic-dose subcutaneous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic-dose subcutaneous enoxaparin (40 mg once daily) for 6 months after 3 months of therapeutic-dose LMWH.
Trial: 35587650
Drug: Relugolix (by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix (by mouth once daily)
Trial: 35588104
Drug: Glabellar onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Glabellar onabotulinumtoxinA injections
Trial: 35588274
Drug: Modified fluid
RxNorm normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified fluid gelatin 4% in a balanced electrolyte solution
Trial: 35588274
Drug: Albumin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (50 g L)
Trial: 35588317
Drug: Idursulfase-IT 10
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase-IT 10 mg or 30 mg administered monthly via IT drug delivery device or lumbar puncture
Trial: 35588317
Drug: Idursulfase-IT treatment
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase-IT treatment
Trial: 35588692
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W for 35 cycles (2 years)
Trial: 35588752
Drug: Tazemetostat 800
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat 800 mg once on day 1 and then twice daily from day 2 onwards (part 1); Tazemetostat 800 mg twice daily starting on day 1 of cycle 1 (part 2)
Trial: 35589164
Drug: Previous statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous statin therapy
Trial: 35589352
Drug: Dolutegravir/lamivudine dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir/lamivudine dual antiretroviral therapy
Trial: 35589352
Drug: Other dual-drug
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other dual-drug and three-drug combinations
Trial: 35589542
Drug: BNT162b2 COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 COVID-19 vaccine, 2 doses
Trial: 35590143
Drug: JAK1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JAK1 inhibitor itacitinib
Trial: 35591977
Drug: IV etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV etoposide 100 mg/m²
Trial: 35592513
Drug: Achieved 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieved 25(OH)D concentrations ≥40 ng/mL
Trial: 35594123
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg/day, 200 mg/day, 400 mg/day)
Trial: 35595617
Drug: SN-5 questionnaire
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SN-5 questionnaire after 4-week treatment
Trial: 35595730
Drug: Pirtobrutinib (LOXO-305),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK)
Trial: 35597904
Drug: Volasertib (250-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (250-350 mg on D1 and D15)
Trial: 35597904
Drug: Volasertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib monotherapy
Trial: 35598186
Drug: vemurafenib/cobimetinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vemurafenib/cobimetinib administered via feeding tube
Trial: 35598441
Drug: SJ733 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (300 mg daily for 3 days)
Trial: 35598441
Drug: SJ733 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (600 mg daily for 3 days)
Trial: 35598441
Drug: SJ733 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (75 mg single dose) + cobicistat (150 mg single dose)
Trial: 35598441
Drug: SJ733 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (300 mg single dose) + cobicistat (150 mg single dose)
Trial: 35598441
Drug: SJ733 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (600 mg single dose) + cobicistat (150 mg single dose)
Trial: 35598441
Drug: SJ733 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJ733 (600 mg single dose) ± cobicistat
Trial: 35600486
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 mg Q2W plus statin therapy (atorvastatin 20 mg/day or rosuvastatin 10 mg/day)
Trial: 35601412
Drug: HMO supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMO supplement
Trial: 35602004
Drug: Nanocovax vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocovax vaccine (25 mcg, 50 mcg, and 75 mcg doses with 0.5 mg aluminium hydroxide adjuvant)
Trial: 35602004
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mg aluminium hydroxide adjuvant only)
Trial: 35602475
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clindamycin and low dose TMP/SMX (CT group)
Trial: 35602475
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of TMP/SMX (T group)
Trial: 35603165
Drug: EGFRvIII-directed CAR
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFRvIII-directed CAR T cell therapy
Trial: 35603278
Drug: Bispecific LV20.19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific LV20.19 CAR T cell therapy
Trial: 35603905
Drug: Neoadjuvant/induction platinum-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant/induction platinum-based combination chemotherapy (NAIC)
Trial: 35603905
Drug: Combination immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immune checkpoint inhibition (cICI)
Trial: 35604212
Drug: Alternative dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative dolutegravir dosing regimens
Trial: 35605011
Drug: Plasma antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma antibodies from SFV-infected individuals
Trial: 35605481
Drug: Cenobamate (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenobamate (12.5, 25, 50, 100, 150, 200 mg/day, target dose 200 mg/day, with further increases to 400 mg/day by 50 mg/day increments every other week)
Trial: 35606646
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate medication prescribing (PIP) detected by a computer algorithm
Trial: 35606731
Drug: ClinTouch DAWN-P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ClinTouch DAWN-P app for daily EPDS assessments
Trial: 35607994
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment in 2015
Trial: 35608376
Drug: 4-week exercise
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week exercise and nutrition prehabilitation program (blood flow restriction exercise and sports nutrition supplement)
Trial: 35608822
Drug: Selinexor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (40 mg on days 1, 8, 15) and Ibrutinib (420 mg daily)
Trial: 35608822
Drug: Selinexor and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor and Ibrutinib combination
Trial: 35609913
Drug: Remdesivir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days) plus standard treatment
Trial: 35609913
Drug: Remdesivir plus
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir plus standard treatment
Trial: 35610084
Drug: 150-300 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-300 g fish/week
Trial: 35610144
Drug: Thyroid hormones
RxNorm normalized name: Thyroid hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormones (TSH, fT3, fT4) as continuous variables
Trial: 35610367
Drug: Resection/local ablative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resection/local ablative therapy (LAT)
Trial: 35610367
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy only
Trial: 35611499
Drug: Durvalumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab monotherapy (10 mg/kg every 2 weeks)
Trial: 35611499
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg for 4 doses, followed by durvalumab 20 mg/kg Q4W)
Trial: 35613775
Drug: Blood tests
RxNorm normalized name: Blood tests, auxiliary products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood tests on Oral Glucose Tolerance Test (OGTT) and haemoglobin A1C (HbA1c)
Trial: 35615627
Drug: Structured active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured active play intervention (combined in-hospital and home-based program, 45-min sessions three times weekly)
Trial: 35615718
Drug: rATG (rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rATG (rabbit antithymocyte globulin) administered intravenously at a dose of 0.8-1.0 mg/kg daily (cumulative dose of 150-200 mg)
Trial: 35616437
Drug: Repetitive task
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repetitive task practice using a combination of robot-assisted therapy and functional arm use in real-world tasks
Trial: 35617646
Drug: CTC enumeration
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC enumeration trajectory in the highest quartile (> 0.12 CTCs/mL annually)
Trial: 35619189
Drug: Nebulized haMSC-Exos
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized haMSC-Exos (2.0 × 10^6 exosomes daily for 5 days)
Trial: 35619611
Drug: Transdermal trigeminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal trigeminal electrical neuromodulation (TTEN) for 4 weeks, daily 20 min sessions
Trial: 35619611
Drug: Transdermal trigeminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal trigeminal electrical neuromodulation (TTEN)
Trial: 35620522
Drug: Nicotinamide riboside
RxNorm normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide riboside (500 mg, 2×/day)
Trial: 35622082
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme medication (Creon)
Trial: 35622315
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W)
Trial: 35623855
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency (SF < 15.0 μg/L)
Trial: 35623855
Drug: Iron insufficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron insufficiency (SF < 20.0 μg/L)
Trial: 35623855
Drug: Iron insufficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron insufficiency (SF < 25.0 μg/L)
Trial: 35623855
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency anemia (IDA) (Hb < 12.0 g/dL and SF < 15.0 μg/L)
Trial: 35623855
Drug: Anemia (Hb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia (Hb < 12.0 g/dL)
Trial: 35623855
Drug: Severe anemia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe anemia (Hb < 8.0 g/dL)
Trial: 35623855
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP > 5.0 mg/L)
Trial: 35623855
Drug: Alpha-1 acid
RxNorm normalized name: Alpha-1 acid glycoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 acid glycoprotein (AGP > 1.0 g/L)
Trial: 35623976
Drug: Information and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information and therapy guides
Trial: 35624056
Drug: Oral combination
RxNorm normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combination of VTS-Aspirin and ketamine (mean ketamine dose 37.8 mg, range 24 mg to 50 mg)
Trial: 35624056
Drug: Oral combination
RxNorm normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combination of VTS-Aspirin and ketamine
Trial: 35624418
Drug: Dexmedetomidine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine at a dose of 0.5 μg/kg, adjusted in 0.1 μg/kg gradients based on previous patient outcomes.
Trial: 35626701
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of human immature dental pulp stem cells (hIDPSC)
Trial: 35627709
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of oral anticoagulants
Trial: 35627709
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antiarrhythmic and diuretic agents
Trial: 35628832
Drug: Chronic OAC
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic OAC (various types including rivaroxaban, dabigatran, apixaban, and vitamin K antagonists)